
Opinion|Videos|September 3, 2024
Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial
Medical experts offer insights on the COMMANDS trial findings.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Discuss the expanded indication of luspatercept in lower-risk myelodysplastic syndromes (based on the COMMANDS trial findings) and its implications for clinical practice.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Sibeprenlimab for Immunoglobulin A Nephropathy
2
Patients Face New Care Complexities as DTC Options Expand
3
Expiring ACA Subsidies and CMS Payment Models Raise Costs for Consumers and Employers
4
Louisiana Delivers Innovative Cancer Treatments, but Ensuring Access Is a Work in Progress
5









































